Based on the Bumrungrad Hospital PCL DRC stock forecast from 0 analysts, the average analyst target price for Bumrungrad Hospital PCL DRC is not available over the next 12 months. Bumrungrad Hospital PCL DRC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bumrungrad Hospital PCL DRC is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Bumrungrad Hospital PCL DRC’s stock price was USD 6.44. Bumrungrad Hospital PCL DRC’s stock price has changed by +0.00% over the past week, +5.23% over the past month and +6.27% over the last year.
No recent analyst target price found for Bumrungrad Hospital PCL DRC
No recent average analyst rating found for Bumrungrad Hospital PCL DRC
Company Overview Bumrungrad Hospital PCL DRC
Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children's, colorectal surgery, complex coronary artery intervention, cornea transplant, dental, diagnostic, dialysis, digestive disease, ear, nose, throat, emergency, endocrinology, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopedics, perinatal, plastic surgery, pulmonary, refractive surgery, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, comprehensive sleep, IVF, hearing and balance, medical, memory, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, vaccine clinics. In addition, it provides spine institute, diagnostic radiology and nuclear medicine, esperance, heart institute, intensive care unit, neurocritical care, nutrition services, pharmacy services, and preventive genomics and integrative medicine services. Further, the company offers clinical research; hospital consulting and management; healthcare personnel development and training; healthcare referral; and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand. Read Less
Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children's, colorectal surgery, comple...Read More
Frequently Asked Questions About Bumrungrad Hospital PCL DRC (BUGDF) Stock
Stock Target Advisor's fundamental analysis for Bumrungrad Hospital PCL DRC's stock is Slightly Bullish .
BUGDF stock's dividend yield is 1.96%.
Our analysis grades BUGDF stock's dividend yield at F. This means that BUGDF stock's dividend yield is above 27% of the stocks in the Medical Care Facilities sector in the OTC exchange.
Based on this BUGDF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on BUGDF's stock to indicate what its average analyst target is.
BUGDF stock's Price/Earning ratio is 29.27.
Our analysis grades BUGDF stock's Price / Earning ratio at F. This means that BUGDF stock's Price/Earning ratio is above 63% of the stocks in the Medical Care Facilities sector in the OTC exchange.
Based on this BUGDF may be a overvalued for its sector.
The last closing price of BUGDF's stock was USD 6.44.
The most recent market capitalization for BUGDF is USD 5.12B.
Unfortunately we do not have enough analyst data on BUGDF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bumrungrad Hospital PCL DRC's stock.
As per our most recent records Bumrungrad Hospital PCL DRC has 0 Employees.
Bumrungrad Hospital PCL DRC's registered address is 33 Sukhumvit Soi 3 (Nana Nua), Bangkok, Thailand, 10110.
You can get more information about it from Bumrungrad Hospital PCL DRC's website at https://www.bumrungrad.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BUGDF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
